Ashvattha Therapeutics to Present at 2021 Sachs 7th Annual Digital Immuno-Oncology Innovation Forum

REDWOOD CITY, Calif.--()--Ashvattha Therapeutics, a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neuro-oncology, neurology and ophthalmology, today announced that it will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually, May 18-20, 2021.

Jeffrey Cleland, Ph.D., Chairman, CEO and President of Ashvattha Therapeutics will provide an overview of the company, and its pipeline enabled by a proprietary hydroxyl dendrimer (HD) technology platform - a differentiated, superior approach to targeted intracellular therapy.

“We are excited to present our strategy in neuro-oncology therapeutics for the first time at the Sachs Immuno-Oncology Forum,” said Jeffrey Cleland, Ph.D., Chairman, CEO & President at Ashvattha Therapeutics. “There remains a significant unmet need in treating primary and metastatic brain cancers with therapeutic agents that can cross the blood brain barrier and precisely target tumor associated macrophages. We are developing an HD imaging agent, D6-B483, to demonstrate uptake of HDs in gliomas and brain metastases. This agent will also be used as a radiotherapeutic. HDTs currently in preclinical studies are designed to manipulate the tumor microenvironment toward a pro-inflammatory state increasing innate immune responses to the tumor.”

Ashvattha’s technology platform consists of HDs that selectively target regions of inflammation within the body. Current cancer treatments have dose-limiting toxicity reducing efficacy, and even precision medicine and targeted therapies lack sufficient specificity to tumors. Most cancer drugs do not cross the blood-brain barrier (BBB) to treat brain cancer. In addition, current immune therapies do not target tumor-associated macrophages (TAMs). Ashvattha’s HDTs widen the therapeutic window and increase the maximum tolerated dose, for better patient outcomes. Its proprietary compounds also target and treat brain tumors with durable effects inside TAMs for up to 30 days. Ashvattha is currently on track to initiate a D6-B483 Phase 1 study in patients with glioblastoma multiforme or brain metastases by end of 2021.

The 7th Annual Immuno-Oncology Innovation Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. Members of the management team will be available for virtual meetings at the conference. For more information, visit the conference website: https://www.sachsforum.com/7ioif-about.html.

About Ashvattha Therapeutics

Ashvattha Therapeutics holds the exclusive rights to a novel hydroxyl dendrimer technology developed at Johns Hopkins University enabling a new class of targeted therapies previously unachievable with traditional drug moieties. Ashvattha are commercializing the technology through new entities established to develop therapeutic opportunities within specific fields and enabled through the use of our dendrimer platform. For more information, visit: www.avttx.com.

Contacts

Investors
Matt Brewer
Ashvattha Therapeutics
matt@avttx.com
303-717-9446

Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744

Release Summary

Ashvattha Therapeutics to Present at 2021 Sachs 7th Annual Digital Immuno-Oncology Innovation Forum.

Contacts

Investors
Matt Brewer
Ashvattha Therapeutics
matt@avttx.com
303-717-9446

Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744